An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Toragen, Inc. Announces the Appointment of Board of Directors and Senior Staff
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
management
Rhea-AI Summary
Toragen, Inc., a biotechnology firm focused on treating HPV-induced cancers, has announced new board appointments. Mr. Paul Engler, a seasoned investor, joins the Board of Directors, while Cheryl Collett has been appointed CFO effective June 20, 2022. Collett, with over 20 years in finance, previously worked at Puma Biotechnology (NASDAQ: PBYI). Dr. Richard Lumpkin will lead Research & Development starting July 1, 2022. Engler commended Toragen’s team and unique platform, highlighting the company's commitment to addressing HPV-related health issues.
Positive
Appointment of Paul Engler to the Board may attract further investments due to his extensive industry experience.
Cheryl Collett's tenure at Puma Biotechnology indicates strong financial leadership and operational experience.
Dr. Richard Lumpkin's extensive biotech research experience could enhance research and development initiatives.
Negative
Engler's lack of direct experience in the biotech sector raises questions about his contributions to the company's strategic direction.
Potential continuity risks as new leadership transitions may affect ongoing projects and investor confidence.
Toragen is focused on uniquely selective drugs targeting cancers caused by the human papillomavirus (“HPV”)
SAN DIEGO--(BUSINESS WIRE)--
Toragen, Inc., a San Diego-based biotechnology company focused on developing, repurposing and commercializing uniquely selective drugs targeting cancers caused by the human papillomavirus (“HPV”), announced today the appointment of Mr. Paul Engler, of Amarillo, Texas, to the Board of Directors of the Company. Additionally, Toragen announced the appointment of Cheryl Collett as CFO, effective June 20, 2022, and Dr. Richard Lumpkin as Director, Research & Development, effective July 1, 2022.
Mr. Engler is the founder of Cactus Feeders. In 1960, he started the first cattle-feeding operation in Texas and grew the company to become the largest cattle-feeding company in the world. At age 93, Paul is extremely active and healthy. He remains actively involved in investments and philanthropic activities of his private foundation, the Paul F. and Virginia J. Engler Foundation.
Mr. Engler stated that, “I invest in people. I was immediately impressed with the team at Toragen. In fact, I have known Dr. Sandra Coufal, Toragen’s CEO, to be an extremely competent medical practitioner and have made investments in other ventures that were successfully directed by Dr. Coufal. We are all aware that HPV can induce a number of cancers and I found Toragen’s platform solution to be unique. I was eager to be a lead investor and welcomed a seat on the board.”
Ms. Collett brings over 20 years’ progressive finance and accounting experience to Toragen. Most recently, Ms. Collett served as CFO of Anivive Lifesciences, an animal-health pharmaceutical company commercializing the first-ever oral lymphoma treatment for dogs. Prior to Anivive, Ms. Collett served as VP, Finance and Accounting for Puma Biotechnology (NASDAQ: PBYI) where she spent nearly a decade growing the company from four employees to over 300, from privately held to public, and from clinical-stage to commercial. Additionally, Ms. Collett has worked in finance and accounting roles at Sierra Scientific Instruments, Cougar Biotechnology, Hythiam and 20th Century Fox after beginning her career in public accounting. She received her degree from California State University, Los Angeles and is a California-licensed CPA.
Richard Lumpkin, PhD, has over 30 years’ experience in early-stage research in biotechnology companies. Dr. Lumpkin previously served as Senior Director at Global Blood Therapeutics becoming the first employee of this Third Rock Ventures founded company. Dr. Lumpkin was also instrumental in spinning off Portola Pharmaceuticals from Millennium Pharmaceuticals and held positions in early-stage research for Cor Therapeutics, Ribogene, Amylin and Corvas International, Inc.Dr. Lumpkin received his undergraduate in Geology and graduate degree in Biochemistry from the University of Missouri, Columbia.
About Toragen
Toragen, founded by Andrew Sharabi, MD, PhD, Associate Professor of Radiation Medicine and Applied Sciences at UC San Diego, is targeting the root cause of virally induced cancers. https://toragen.com.
Who is the new CFO of Toragen and what is her background?
Cheryl Collett is the new CFO of Toragen, effective June 20, 2022. She has over 20 years of finance experience and previously served as CFO at Anivive Lifesciences and in various roles at Puma Biotechnology.
What is the significance of Paul Engler's appointment to Toragen's Board?
Paul Engler's appointment is significant as he is a seasoned investor with a successful background in business, which could bring further investment opportunities for Toragen.
When did Dr. Richard Lumpkin start his role at Toragen?
Dr. Richard Lumpkin began his role as Director of Research & Development at Toragen on July 1, 2022.
What is Toragen's main focus as a biotechnology company?
Toragen focuses on developing selective drugs targeting cancers caused by the human papillomavirus (HPV).
What potential impact does the management change have on Toragen?
The management change could introduce new perspectives and strategies, but it also poses risks related to continuity and investor confidence.
